SCHEMBL2865472

SCHEMBL2865472

CC(=C(C)c1ccc2c(c1)-c1ccccc1C2)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRD5A2 P31213 2/20 0.56
▸ CYP1A2 P05177 4/20 0.46
▸ HTR2C P28335 2/20 0.46
▸ HTR2B P41595 2/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ MAOA P21397 1/20 0.46
▸ SLC6A2 P23975 1/20 0.46
▸ SLC6A4 P31645 1/20 0.46
▸ MAPT P10636 4/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ HPGD P15428 3/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ ADRA1D P25100 1/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867701 0.81 SRD5A2 (0.53) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL13236269 0.81 MAPT (0.70) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL2868771 0.79 SRD5A2 (0.51) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL3105349 0.79 SRD5A2 (0.86) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL29709873 0.79 SRD5A2 (0.86) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL31069845 0.79 SRD5A2 (0.86) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL2864393 0.78 SRD5A2 (0.50) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL28119578 0.77 SRD5A2 (0.83) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL30912172 0.74 SMN1; SMN2 (0.64) SRD5A2CYP1A2HTR2CHTR2BADRA2A
SCHEMBL5016641 0.74 SMN1; SMN2 (0.64) SRD5A2CYP1A2HTR2CHTR2BADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834204-B2 Fluorene derivative, transition metal compound, catalyst for olefin polymerization, and process for producing olefin polymer MITSUI CHEMICALS, INC. (JP) 2010-11-16 — — US disclosed
US-20090253876-A1 Fluorene Derivative, Transition Metal Compound, Catalyst for Olefin Polymerization, and Process for Producing Olefin Polymer MITSUI CHEMICALS, INC. 2009-10-08 — — US disclosed
EP-1900715-A1 FLUORENE DERIVATIVE, TRANSITION METAL COMPOUND, CATALYST FOR OLEFIN POLYMERIZATION, AND PROCESS FOR PRODUCING OLEFIN POLYMER Mitsui Chemicals, Inc. (JP) 2008-03-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253876-A1 Fluorene Derivative, Transition Metal Compound, Catalyst for Olefin Polymerization, and Process for Producing Olefin Polymer AFF4, OR10J3, DRD1 SRD5A2 465/4885CYP1A2 666/4885HTR2C 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback